ProCE Banner Activity

PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm

Podcast Episodes
Listen to Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live CCO webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer.

Released: October 14, 2021

Expiration: October 13, 2022

Share

Faculty

Nicoletta Colombo

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Philipp Harter

Philipp Harter, MD, PhD

Deputy Director
Department of Gynecology and Gynecologic Oncology
Evang. Kliniken Essen-Mitte
Essen, Germany

Alexandra Leary

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Nicoletta Colombo, MD, has disclosed that she has received consulting fees from AstraZeneca, BIOCAD, Clovis Oncology, Eisai, GlaxoSmithKline, ImmunoGen, Mersana, MSD/Merck, Novartis, Pfizer, Pharmamar, Roche, Takeda, and Tesaro.

Philipp Harter, MD, PhD

Deputy Director
Department of Gynecology and Gynecologic Oncology
Evang. Kliniken Essen-Mitte
Essen, Germany

Philipp Harter, MD, PhD, has disclosed that he has received funds for research support from AstraZeneca, Clovis, Genmab, GlaxoSmithKline, ImmunoGen, MSD/Merck, and Roche and consulting fees from AstraZeneca, Clovis, GlaxoSmithKline, ImmunoGen, MSD/Merck, Roche, and Stryker/Zailab.

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France

Alexandra Leary, MD, PhD, has disclosed that she has received funds for research support from Ability, AstraZeneca, Clovis Oncology, GlaxoSmithKline, Merck Sharp & Dohme, and Tesaro and consulting fees from Ability, AstraZeneca, BIOCAD, Clovis Oncology, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Seattle Genetics, Tesaro, and Zentalis.